China Business Law Journal recognized Sidley as “Firms of the Year 2019” for the following practice areas:
- Healthcare, Pharma and Life Sciences
- Real Estate and REIT
- Structured Finance and Securitization
In addition, the publication also recognized three deals on which Sidley provided legal advice as “Overseas Deals of the Year” in 2018:
- Ascletis Pharma’s Hong Kong IPO
- Haidilao’s Hong Kong IPO
- C.H.M.T. purchases The Center in Hong Kong
Sidley acted as international counsel to Ascletis — an integrated anti-viral platform which focuses on developing and commercializing drugs against HCV, HIV and HBV — on its August 2018 listing on the Stock Exchange of Hong Kong. It was the first biotechnology company to list successfully since the new Hong Kong listing regime took effect in April 2018, and also the largest IPO globally of a pre-revenue biotechnology company in recent years.
Chinese restaurant brand Haidilao raised US$963 million on pricing its shares at the top of an indicated range in its Hong Kong IPO — making it the fifth largest listing in Hong Kong in 2018. Sidley acted as Hong Kong and U.S. counsel to Haidilao.
Further, Sidley was among the firms providing legal counsel to C.H.M.T. on its purchase of The Center in Hong Kong. At US$5.2 billion, it is the world’s most expensive real estate transaction to date for a single building.
The three winning deals cover the capital markets and real estate business areas, reflecting the comprehensive strength of the firm. The deals were selected based on their overall significance, complexity and innovative nature, along with their size and broader interests.